Griselimycin is a natural cyclic depsipeptide antibiotic isolated from Streptomyces species that has been investigated for its potent activity against Mycobacterium tuberculosis, including drug-resistant… Read more
Griselimycin is a natural cyclic depsipeptide antibiotic isolated from Streptomyces species that has been investigated for its potent activity against Mycobacterium tuberculosis, including drug-resistant strains. By binding to the sliding clamp of bacterial DNA polymerase, specifically the DnaN subunit, this compound effectively inhibits DNA replication. Within pharmaceutical research and development, related products such as impurities, metabolites, and stable isotope labelled standards are critical for comprehensive analytical testing. These compounds are employed by laboratories to facilitate accurate impurity profiling, rigorous method validation, and consistent quality control of Griselimycin formulations. By providing reliable reference standards, these materials support the precise identification and quantification of analytes in complex matrices, ensuring that pharmaceutical development programs can maintain high standards of structural and purity verification throughout the lifecycle of drug analysis.